Table 2

Time to sample acquisition for UM and FHCRC cohorts

CharacteristicUM discovery cohort (n = 35)UM validation cohort (n = 109)P value*FHCRC validation cohort (n = 211)
No cGVHD (n = 18)De novo cGVHD (n = 17)P valueNo cGVHD (n = 64)De novo cGVHD (n = 45)P valueNo cGVHD (n = 33)New-onset cGVHD (n = 86)Established cGVHD (n = 92)P value†
Time post-HCT, days            
 Median 102 103 .25 135 154 0.25 .14 369 256 619 <.001 
 Range 94-189 97-221  92-205 55-364   161-3641 92-915 196-8974  
Time post-cGVHD onset, days       .45     
 Median — 0  — 0  — 11 389  
 Range — −50 to +12 — — −42 to +35 — — 0-91 92-1168 <.001‡ 
CharacteristicUM discovery cohort (n = 35)UM validation cohort (n = 109)P value*FHCRC validation cohort (n = 211)
No cGVHD (n = 18)De novo cGVHD (n = 17)P valueNo cGVHD (n = 64)De novo cGVHD (n = 45)P valueNo cGVHD (n = 33)New-onset cGVHD (n = 86)Established cGVHD (n = 92)P value†
Time post-HCT, days            
 Median 102 103 .25 135 154 0.25 .14 369 256 619 <.001 
 Range 94-189 97-221  92-205 55-364   161-3641 92-915 196-8974  
Time post-cGVHD onset, days       .45     
 Median — 0  — 0  — 11 389  
 Range — −50 to +12 — — −42 to +35 — — 0-91 92-1168 <.001‡ 
*

Difference between discovery and validation.

†

Difference between No cGVHD and new-onset cGVHD.

‡

Difference between new onset vs established.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal